Abstract: A crystalline form of a high-stability nor-ursodeoxycholic berberine salt and a preparation method therefor are provided. The crystalline form has the following structural formula. In X-ray powder diffraction of the crystalline form, a 2? diffraction angle has characteristic peaks at 3.54+/?0.2 degrees, 7.13+/?0.2 degrees, 13.14+/?0.2 degrees, 15.95+/?0.2 degrees, 16.40+/?0.2 degrees, 18.64+/?0.2 degrees, 24.90+/?0.2 degrees, 25.76+/?0.2 degrees and 26.30+/?0.2 degrees.

Abstract: A compound represented by formula (I) is effective in inhibiting the growth of Clostridium difficile. Compared with nitazoxanide and other antibiotics, the compound also has significantly less influence on intestinal probiotics and lower toxic side effects while significantly inhibiting the activity of Clostridium difficile, and the disease is not easy to relapse after the drug is stopped.

Abstract: A compound as a receptor-interacting protein (RIP) inhibitor, a preparation method therefor, and a use thereof, which relate to the field of chemical medicines, are provided. The compound is a compound as represented by formula (I), or a salt thereof, or a stereoisomer thereof, or a solvate thereof, or a prodrug thereof. The compound has good inhibitory activity on humanized RIP1 kinase, and can be used for preparing drugs for resisting inflammation, resisting tumors and the like.

Abstract: A compound as represented by formula I-1, or a pharmaceutically acceptable salt, a stereoisomer, or a solvate thereof are effective in reducing ALT, AST and ALP as well as helpful in treating hepatic pathological injuries (e.g. hepatocyte steatosis). The compound has wide application prospects in the preparation of a drug for preventing and/or treating liver diseases such as fatty liver, hepatic fibrosis and liver cirrhosis.

Abstract: The present disclosure provides a compound represented by formula (I), or a salt or a stereoisomer thereof. The compound is capable of effectively inhibiting germination of Clostridium difficile spores with a significant bacteriostatic activity. The compound has an excellent prospect for use in preparation of a drug for preventing and/or treating a C. difficile-caused infectious disease, recurrence of the C. difficile-caused infectious disease, or a complication of the C. difficile-caused infectious disease.

Abstract: The invention provides the use of ursolic acid saponin and oleanolic acid saponin of formula (I) in preparing medicaments for increasing leucocytes and/or platelets. The invention also provides a pharmaceutical composition containing the same compound. The invention utilizes the cheap and accessible ursolic acid and oleanolic acid which are widely present in natural plants as raw materials, introduces monosaccharyls or oligosaccharyls by structural modification. It is proved by pharmacological tests that the compound of formula (I) have an activity of obviously increasing leucocytes and/or platelets.

Abstract: The invention provides the use of ursolic acid saponin and oleanolic acid saponin of formula (I) in preparing medicaments for increasing leucocytes and/or platelets. The invention also provides a pharmaceutical composition containing the same compound. The invention utilizes the cheap and accessible ursolic acid and oleanolic acid which are widely present in natural plants as raw materials, introduces monosaccharyls or oligosaccharyls by structural modification. It is proved by pharmacological tests that the compound of formula (I) have an activity of obviously increasing leucocytes and/or platelets.